Table 1.
L-NAME impact on cardiac function in ZSF-1 rats treated with finerenone.
| ZSF1 + Fine n = 8 | ZSF1 + Fine + L-NAME n = 3 | |||||
|---|---|---|---|---|---|---|
| SBP | 195 | ± | 5.5 | 202 | ± | 5.8 |
| HR | 327.3 | ± | 6.8 | 291 | ± | 7.0 * |
| LVESP | 191.5 | ± | 6.4 | 205.4 | ± | 5.5 |
| dP/dt max | 11,467.8 | ± | 504.4 | 9757 | ± | 419.0 * |
| LVESPVR | 30.8 | ± | 1.9 | 29.7 | ± | 1.5 |
| LVEDP | 6.05 | ± | 0.7 | 14.6 | ± | 3.0 * |
| dP/dt min | 9979.5 | ± | 641.4 | 4420.6 | ± | 177.4 * |
| Tau | 12.38 | ± | 0.5 | 17.29 | ± | 0.5 * |
| LVEDPVR | 2.86 | ± | 0.3 | 3.76 | ± | 0.1 * |
| LV tissue perfusion | 6.9 | ± | 0.3 | 3.6 | ± | 0.2 * |
Data are presented as the mean ± SEM; n = 3–8. * p < 0.05 vs. ZSF-1 + Fine. (SBP) systolic blood pressure (mmHg), (HR) heart rate (bpm), (LVESP) left ventricle end-systolic pressure (mmHg), (dP/dt max) contractility (mmHg/s), (LVESPVR) left ventricle end-systolic pressure–volume relationship (mmHg/RVU), (LVEDP) left ventricle end-diastolic pressure (mmHg), (dP/dt min) relaxation (mmHg/s), (Tau) time constant of relaxation (msec), (LVEDPVR) left ventricle end-diastolic pressure–volume relationship (mmHg/RVU) and (LV tissue perfusion) left ventricle tissue perfusion (mL/min).